Small But Mighty Sinus Implant

PROPEL Mini, a smaller version of PROPEL, offers the same drug dose and clinical benefits as PROPEL. Physicians can now offer localized drug delivery to patients undergoing frontal sinus surgery with less extensive surgery and smaller anatomy, allowing more sinus sufferers to benefit from the only products in sinus surgery backed by Level 1-A evidence which improves sinus surgery outcomes.1

PROPEL Mini Mometasone Furoate Dissolvable Sinus Implant LogoPROPEL Mini is the first and only product clinically proven to improve frontal sinus surgery outcomes.2 Its lower profile and curved delivery system offer precise, consistent, and easy placement.

The PROPEL Mini dissolvable sinus implant props the frontal or ethmoid sinus open while releasing an advanced corticosteroid (mometasone furoate) directly to the sinus over 30 days post-surgery. Results show that PROPEL Mini is superior to surgery alone, reducing the need for oral steroids and additional surgical procedures.3,4

PROPEL Mini Frontal Sinus Stent Product Image

PROGRESS Study:
PROPEL Mini Maintains Frontal Sinus Opening Following Sinus Surgery

PROGRESS Study: An 80-patient prospective, randomized, blinded, controlled trial evaluated outcomes of frontal sinus surgery using balloons and/or traditional instruments with PROPEL Mini compared to the standard care, surgery alone.5

PROPEL Mini Progress Study - Surgery with PROPEL Mini Sinus Implant vs Surgery Alone

PROPEL Mini Sinus Implant Product Details

  • Indicated for the Ethmoid and Frontal Sinuses
  • Same Drug Dose and Elution Profile as PROPEL
  • 16mm Nominal Length
U.S. Instructions for Use
EU Instructions for Use
PROPEL Mini Dissolvable Sinus Stent Product Photo

Learn More About
PROPEL Sinus Implants

We have compiled resources to help physicians and patients better understand how the PROPEL steroid-releasing implant works to improve sinus surgery outcomes.

Physician Resources
Patient Resources

11Han JK, Marple BF, Smith TL, et al. Int Forum Allergy Rhinol. 2012; 2:271-279.
2Smith T, Singh A, et al. Laryngoscope. 2016.
3Kennedy DW, Wright ED, Goldberg AN. Laryngoscope. 2000; 110(S94):29-31.
4Kennedy DW. Expert Review of Respiratory Medicine. 2012; 6(5):493-498.
5Smith T, Singh A et al. Laryngoscope. 2016.

The PROPEL sinus implants are intended for use after sinus surgery to maintain patency and to locally deliver steroid to the sinus mucosa: PROPEL for use in the ethmoid sinus, PROPEL Mini for use in the ethmoid sinus and frontal sinus opening, and PROPEL Contour for use in the frontal and maxillary sinus ostia. The implants are intended for use in patients ≥18 years of age. Contraindications include patients with intolerance to mometasone furoate (MF) or a hypersensitivity to bioabsorbable polymers. Safety and effectiveness of the implants in pregnant or nursing females have not been studied. Risks may include, but are not limited to, pain/pressure, displacement of implant, possible side effects of intranasal MF, sinusitis, epistaxis, and infection. For complete prescribing information see IFU at www.IntersectENT.com. Rx only.

The PROPEL ® Mini implant, delivery system, and/or the use of the PROPEL® Mini implant/delivery system in a method may be covered by one or more U.S. and/or foreign patents, including U.S. Patent Nos. 7,544,192, 7,662,141, 7,662,142, 7,713,255, 7,951,130, 7,951,131, 7,951,133, 7,951,135, 8,109,918, 8,535,707, 8,585,730, 8,585,731, and 8,986,341. Other patent applications are pending. This page is intended to serve as notice under 35 U.S.C. § 287(a).